



Asep Medical Holdings Inc.

FOR IMMEDIATE RELEASE

Asep Medical Announces Closing of Private Placement of Convertible Debentures and Corporate Update

VANCOUVER, BC, May 1, 2026 — **Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8)** is pleased to announce, that further to its news release of April 29, 2026, that it has closed its private placement on April 30, 2026, and has issued 200 debentures (the "**Debentures**") for gross proceeds of \$200,000 (the "**Offering**").

The Debentures will bear interest at the rate of 12% per annum and will mature on the date that is twelve (12) months from the date of issuance (the "**Maturity Date**"). The Company anticipates using the proceeds from the Offering for general working capital purposes. Prior to the Maturity Date, the principal amount of the Debentures may be converted, at the option of the holder, into common shares of the Company (the "**Conversion Shares**") at a conversion price equal to \$0.31 per Conversion Share. The Debentures and Conversion Shares are collectively referred to herein as the "**Securities**".

All securities issued in connection with the Offering are subject to a statutory hold period expiring four months and one day after the date of issuance of the Debentures. The Company benefited from a waiver granted by the Canadian Securities Exchange (the "**CSE**") of the five-day advance notice requirement prior to closing.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

Further, the Company announces that Thomas O'Shaughnessy resigned as a director on April 30, 2026. The Company wishes to thank Mr. O'Shaughnessy for his contributions to the Company.

ABOUT ASEP MEDICAL HOLDINGS INC.

Asep Medical is a standout biotechnology research and development company based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under



Asep Medical Holdings Inc.

the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists. Asep holds a controlling interest in two private subsidiary companies — Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

FOR MORE INFORMATION, PLEASE CONTACT

Chris Dallin, Marketing Director

ASEP Medical Holdings Inc.

E. chris@asepmedical.com

T. +1 (604) 362-3654

FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plans," "continues," "expects," "projects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include, but are not limited to, statements with respect to the details of the Offering, including the proposed size, timing and the expected use of proceeds and the receipt of regulatory approval for the Offering. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management on the date the statements are made and are subject to a variety of risks, including the expectations of management regarding the use of proceeds of the Offering, risks associated with the business of the Company, the risk that the Company's products may not perform as expected, may not receive regulatory approvals, or may not generate revenue as anticipated. Additional risk factors are identified in the Asep Medical Holdings Inc. prospectus dated November 9, 2021, and in the Company's management discussion and analysis, available for review under the Company's profile at www.sedarplus.ca. Asep Medical Holdings Inc. undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES